Changes In Macular Thickness Research Articles

Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

To determine the relation between retinal microstructural changes and the response to 577-nm subthreshold micropulse laser (SML) treatment in chronic central serous chorioretinopathy (cCSC). This retrospective study included 39 eyes of 39 patients with cCSC, treated with the 577-nm SML. The eyes were evaluated in three groups: complete remission, partial remission, and failure groups. The presence of some baseline retinal microstructural changes, thickness of the outer nuclear layer (ONL), status of the ellipsoid zone (EZ), and retinal pigment epithelium (RPE) were evaluated. The changes in central macular thickness (CMT), subretinal fluid (SRF) height, and best-corrected visual acuity (BCVA) were calculated. There were 14, 13, and 12 eyes in the complete remission, partial remission, and failure group, respectively. The baseline EZ and RPE were found intact in 71.4% and 64.3% of the eyes in the complete remission group, respectively; however, these rates were respectively 25% and 16.7% in the failure group (p < 0.05). Extrafoveal foci were present in 35.7% of the eyes in the complete remission group, but none was found in the failure group (p < 0.05). Although there was no statistically significant difference, the baseline ONL thickness was higher, and the hyperreflective dots, retinal bumps, subretinal fibrinous exudates, and PEDs were seen less in the complete remission group. The changes of the BCVA were not significant in any of the groups at the last visit (p > 0.05). The presence of baseline intact EZ and RPE, and extrafoveal foci can potentially be used as predictors of the SML treatment success in cCSC.

Assessment of macular thickness changes by OCT in asymptomatic subjects at high genetic risk of developing Alzheimer’s disease

PurposeAlzheimer’s diseases is a neurodegenerative disease, whose signs can appear decades before clinically detectable symptoms. In addition to age, genetic factors are one of the most important risk factors. The aim of the present study was analyzed the macular thickness changes by optical coherence tomography (OCT) in subjects who have a first‐degree family history of AD and are carriers of ɛ4 allele for the ApoE, which are two of the main risk factors for developing the disease.MethodsA complete eye examination and a macular OCT were performed in 64 participants, who were free of ocular pathology. The two study groups were formed by 35 subjects with a family history of AD (FH+) and ApoE ɛ4 carriers and 29 age‐matched control subjects without a family history of AD (FH‐) and ApoE ɛ4 non‐carriers.ResultsWe found a statistical significant thinning (p &lt; 0.05) in FH+ ApoE ɛ4 carriers compared to FH‐ ApoE ɛ4 non‐carriers in the next sectors and layers: the foveal area of the macular retinal nerve fiber layer (11.89 ± 1.95, FH+ vs 12.86 ± 1.62, FH‐); the inferior and nasal sectors, both in the outer (26.77 ± 2.74, FH+ vs 28.17 ± 2.82, FH‐) (29.49 ± 2.89, FH+ vs 30.93 ± 3.85, FH‐) and inner (40.49 ± 2.51, FH+ vs 42.10 ± 3.48, FH‐) (41.94 ± 2.74, FH+ vs 43.52 ± 3.57, FH‐) macular ring in the inner plexiform layer; the foveal area (18.82 ± 3.61, FH+ vs 21.21 ± 3.88, FH‐) and the inferior sector in the outer macular ring (30.91 ± 2.72, FH+ vs 32.10 ± 2.81, FH‐) in inner nuclear layer, and the inferior sector of the outer macular ring (27.60 ± 2.75, FH+ vs 29.97 ± 3.82, FH‐) in outer plexiform layer.ConclusionsThe slight retinal thickness changes measured by OCT, that appear in the macular area in asymptomatic subjects at high genetic risk for the development of AD, could be used as an early biomarker of the disease.

İris Kıskaçlı Arka Kamara Lens İmplantasyonu Sonrası Makula Kalınlığı Değişimi: Bir Yıllık İzlem ve Skleral Fiksasyon ile Karşılaştırma

Objective: To evaluate longitudinal changes in macular thickness after retropupillary iris claw intraocular lens (RP-ICIOL) implantation in eyes with post-cataract aphakia and to compare the results with scleral fixated intraocular lens (SFIOL). Material and Methods: The patients were enrolled between 2013 to 2016. Patients were divided into two groups as the ones with RP-ICIOL implanted eyes and SFIOL implanted eyes. Preoperatively and within 1 year postoperatively macular thickness were analysed. Results: RP-ICIOL group consisted of 22 eyes of 22 patients, SFIOL group consisted of 36 eyes of 36 patients. In RP-ICIOL group, statistically significant thickening in central foveal [1 mm, central foveal thickness (CFT)] macular thicknesses was observed firstly at 1st week and progressively increased during the 3 months (p0.050). CME was observed in 1 eye in RP-ICIOL group (4.54%), and 2 eye in SFIOL group (5.55%). Conclusion: The transient and subclinical macular thickening presented in all macular zones after RPICIOL implantation. These thickening started at first week, and progressively increased in the period of 3 months, then it reduced to baseline values at 1 year postoperatively. RP-ICIOL and SFIOL have similar effects on macular thickening.

Evaluation of Choroidal Thickness after Uncomplicated Phacoemulsification Surgery Using Optical Coherence Tomography

Phacoemulsification is an invasive procedure that has become the most common intraocular surgery and usually improves the visual outcome. We aimed to evaluate the potential changes in the subfoveal choroidal thickness (SFCT) after cataract surgery, using Enhanced Depth Imaging OCT. The study was applied on 30 eyes of 30 patients with no medical or ocular disorder and no history of previous ocular surgery . 15 males and 15 females , divided into two groups : group A (15 eyes) – underwent cataract surgery without using non-steroidal anti-inflammatory eye drop before surgery. group B (15 eyes) – will underwent cataract surgery with the use of non-steroidal anti-inflammatory eye drop 3 times ( one drop every 20 mins for hour ) just before surgery and screened to meet the inclusion criteria. Each patient was examined by EDI-OCT four times, one of them done in the day before surgery and three others after surgery in D7, M1 and M3. Our results confirm slight increases in macular thickness start 7 days after surgery and the lastest was one month after surgery. These changes in macular thickness eventually return normally near 3 months after surgery. There was no significant difference in B-group which administered NSAIDs before surgery. Uncomplicated phacoemulsification induces nonpathologic increases in retinal macular thickness probably due to the inflammatory insult of the surgery; however these changes are not accompanied by significant changes in choroidal thickness.

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration.

Objective:Predominantly hemorrhage represents one of the possible manifestations of choroidal neovascularisation (CNV) in eyes with age-related macular degeneration (AMD). The purpose of this study is to evaluate the effecte of ranibizumab treatment in patients with predominantly hemorrhagic CNV secondary to AMD.Methods:Twenty-five patients with predominantly hemorrhagic choroidal neovascularization due to AMD with at least three ranibizumab injections and followed up for at least 12 months were included in the study. The months of follow-up were recorded (baseline, 3rd, 6th, and 12th months). The change in central macular thickness (CMT) on optical coherence tomography, visual acuity (VA) in ETDRS letters, and lesion size on fundus fluorescein angiography were evaluated.Results:The mean age of the patients was 68.1±5.7 (range: 63–82) years, the mean follow-up was 19.9±14.5 (range: 12–67) months, and the mean number of injections was 4.0±1.4 (range: 3–15). The initial VA was 39.3±17.9 (range: 1–65) letters, CMT was 272.7±104 (range: 164–587) μm, and the initial lesion width was 11.4±10.5 (range: 1.3–45.7) mm2. The VA was 41.4±20.1 (range: 5–75) and 36.9±21.8 (range: 4–80) letters (p=0.150), CMT was 270.7±110 (range: 159–570) and 230.4±108 (range: 109–667) μm (p=0.009) and the lesion width was 10.9±11.5 (range: 1.1–39.7) and 10.4±11.6 (range: 1.2–44.3) mm2 at 6th and 12th month, respectively. No factor was found to be associated with final CMT.Conclusion:Although the final visual outcome is limited by the progression of the disease, hemorrhagic lesions treated with ranibizumab have stable anatomical outcome.

Evaluation of change in intraocular pressure and macular thickness after Nd: YAG laser posterior capsulotomy

Purpose: To evaluate the changes in intraocular pressure and macular thickness after Nd: Yag laser posterior capsulotomy. Methodology: This prospective study included 91 eyes of 78 patients who were diagnosed as posterior capsule opacification (PCO), following uncomplicated cataract surgery. All the patients were examined preoperatively and 1 hour post-procedure, 1 week and 4 weeks after Nd: YAG capsulotomy. IOP and macular thickness of all the patients was measured by Goldmann applanation tonometry and optical coherence tomography (OCT), respectively before performing the procedure and at subsequent visits. Patients were divided into two groups based on energy used (Group I ≤50 mJ, Group II >50 mJ). None of the patients received prophylactic antiglaucoma medications either before or after the procedure. Results: There were 42 males and 36 female patients included in the study. Mean age of the patients was 53.87 ± 10.24 years (45-80 years). Mean total energy levels were 38.64±13.92 mJ in Group I and 85.76±22.10 mJ in Group II. In Group I, IOP did not increase at 1 hour postoperatively (P=0.063) and was within normal limits at 1 week and 4 weeks. In Group II, IOP increased at 1 hour postoperatively (P

Intravitreal Ranibizumab versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema

Objectives:This is a retrospective, comparative evaluation of the short-term efficacy and safety of intravitreal ranibizumab (IVR) and IVR combined with posterior subtenon triamcinolone acetonide (STA) in the treatment of diabetic macular oedema (DME).Methods:A total of 79 pseudophakic eyes of 57 patients with DME who underwent IVR injection treatment were examined retrospectively. All of the patients were treatment-naive. In the study group (STA+IVR), consisting of 30 eyes of 39 patients, the STA and IVR were administered in the first treatment session simultaneously, followed by 2 consecutive monthly IVR injections. In the control group (IVR only) comprised 40 eyes of 27 patients, 3 consecutive monthly IVR injections were administered. Patients with serous retinal detachment (SRD) according to optical coherence tomography images were identified in both groups for subgroup analyses. The primary outcome measures were changes in central macular thickness (CMT), best corrected visual acuity (BCVA), and the intraocular pressure (IOP) at 1, 2, and 3 months post-injection.Results:There was no statistically significant difference between the demographic characteristics of the patients’ baseline BCVA and CMT measurements (p>0.05). For the IVR group, the mean pre-treatment CMT and BCVA was 421.20±89.10 μm and 0.42±0.24 logMAR, respectively. After the third injection, the mean was 308.12±59.07 μm and 0.20±0.12 logMAR, respectively. The combined treatment group baseline measurements were 454.50±122.52 μm and 0.54±0.29 logMAR, respectively. After the third injection, the mean was 294.22±50.33 μm and 0.27±0.21 logMAR, respectively. The decrease was statistically significant for both groups (p=0.001). Comparison of the CMT within groups revealed a statistically significant difference in favor of the combined group after the second injection (p=0.017). There was no statistically significant difference in the BCVA gains between groups (p>0.05). Patients with SRD were evaluated as a subgroup, and at the first month, the mean gain in CMT was -71.63±57.98 μm in the control group and -123.61±93.46 μm in the study group (p=0.048). The required anti-glaucomatous treatment was statistically significant in the combined group (p=0.008).Conclusion:Both treatments provided improvement in BCVA and CMT and can be considered functional and anatomically effective treatment options for DME.

Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results.

This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.

Changes of retinal thickness in macular area of myopia children

Objective: To study the changes of macular retinal thickness in children with moderate and low myopia by frequency domain OCT. Methods: 108 school-age children aged 7-12 years were selected and enrolled into the group. Among them, 58 cases (116 eyes) with simple moderate and low myopia in the myopia group and 50 cases (100 eyes) with straight eyes in the emmetropia group. The retinal thickness in different parts of macular area was compared between the two groups, and the correlation between retinal thickness in different parts of macular area and diopter and axial length was analyzed by Pearson correlation analysis. Results: The length of eye axis in moderate and low myopia group was longer than that in emmetropia group, and the difference was statistically significant (P &lt; 0.05). There was no significant difference in CMT(Central Macular Thickness) and I-AMT(average macular thickness of inner circle) between the two groups (P &gt; 0.05). The AMT(Average Macular Thickness) and O-AMT(average macular thickness of outer circle) in moderate and low myopia group were lower than those in emmetropia group, and the differences were all statistically significant (P &lt; 0.05). The thickness of the retina below the macula and the nasal side was positively correlated with the refractive power in patients with moderate to low-grade myopia (r=0.201, 0.302, P＜0.05), and the thickness of the retina around the macula was negatively correlated with the refractive power (r=-0.326, P＜0.05). Conclusion: There is no significant difference in macular central retinal thickness between children with moderate and low myopia and normal children, and the thickness of paracentral retina tends to become thinner with the deepening of myopia.

Micropulse laser in patients with refractory and treatment-naïve center-involved diabetic macular edema: short terms visual and anatomic outcomes.

Purpose:The purpose of the study is to describe visual and anatomic outcomes of 5774nm micropulse laser photocoagulation in eyes with either treatment-naïve or refractory diabetic macular edema (DME) at 3 months.Methods:This was a prospective case series that recruited 23 consecutive patients (33 eyes) with center-involved DME that was either treatment-naïve or had not responded to prior treatment. Micropulse therapy was performed with the Easy Ret 577 (Quantel Medical, Cournon d’Auvergne, France) diode laser in a high-density manner in eyes with treatment-naïve or refractory DME. The primary outcome was the change of best-corrected visual acuity (BCVA; logMAR) at 1 and 3 months. Secondary outcomes were changes in the central macular thickness (CMT), thickness area, macular volume, and macular capillary leakage at 1 and 3 months.Results:There were no significant changes in BCVA at 3 months, with mean ± standard deviation (SD) of −0.08 ± 0.01 (p = 0.228) and + 0.01 ± 0.01 (p = 0.969) for treatment-naïve and refractory groups, respectively. The change in CMT at 3 months was statistically but not clinically significant in the treatment-naïve group only (mean ± SD; –30 ± 130 µm; p = 0.011). The macular volume and area thickness change were not statistically significant (p = 0.173 and p = 0.148 for macular volume and area thickness, respectively) in the treatment-naïve group. There was no difference concerning the leakage area in both groups. No adverse events were reported.Conclusion:We concluded that micropulse 577nm laser therapy maintained the visual acuity and macular thickness at 3 months in both treatment-naïve and refractory DME.

Water-Drinking Test in Central Serous Chorioretinopathy.

Purpose:To evaluate choroidal changes in central serous chorioretinopathy (CSCR) patients after water-drinking test (WDT).Methods:This prospective study included treatment-naïve acute and chronic CSCR eyes and healthy controls. Intraocular pressure and optical coherence tomography measurements with choroidal vascular index (CVI) measurements were done at baseline. Patients were asked to drink 1 L of water, and tests were repeated at 15, 30, and 45 min.Results:Fifty-six eyes from 42 patients were enrolled. Choroidal area, luminal area, and stromal area were higher at baseline in eyes with acute CSCR compared to healthy controls. Chronic CSCR eyes showed an increase in choroidal area and stromal area and a decrease in the luminal area at 15 min. There was a significant decrease in CVI at 30 and 45 min in chronic CSCR and CVI at 45 min in fellow eyes of acute CSCR. Repeated-measures analysis of variance (ANOVA) showed a significant change in central macular thickness in acute CSCR, choroidal thickness in fellow eyes of acute CSCR, stromal area, and total choroidal area in chronic CSCR. Mixed model ANOVA showed that the change in various choroidal parameters seen had no interaction with the eye type.Conclusion:Although change in various parameters was seen in acute CSCR, chronic CSCR, and fellow eyes of acute CSCR following WDT, the change was not significantly different among the groups.

Efficacy of Intravitreal Bevacizumab in Chronic Central Serous Chorioretinopathy in Terms of Mean Reduction of Central Macular Thickness in Pakistani Patients

Background: Central serous chorioretinopathy (CSCR) is an idiopathic condition described by serous neurosensory retinal detachment at the posterior pole, usually associated with serous retinal pigment epithelial detachment (PED). CSCR patients as a rule have good visual prognosis. In most of the patients, CSCR is self-limiting and patients regain the last visual acuity. However, some patients may have visual disability due to permanent RPE and photoreceptor damage. Objective: The objective of the study is to determine the effect of intravitreal Bevacizumab in cases of chronic central serous chorioretinopathy in terms of mean change in central macular thickness. Study Design: Interventional experimental study. Settings: The study was conducted in Department of Ophthalmology, Allied Hospital, Faisalabad Pakistan. Duration: 2 years from January 2017 to December 2018. Methodology: An aggregate of 95 cases were recruited for the study. Study included both male and female patients with diagnosis of chronic CSCR (at least 6month duration). Best corrected visual acuity, Intra Ocular Pressure on Goldman applanation Tonometer and Optical coherence tomography on Optovue were recorded of both eye of all patients. Before starting the treatment, informed consent was signed by every patient and they were called on the day of injection. Intravitreal off label Bevacizumab (1.25/0.05ml) was given through pars plana in operation theater under aseptic conditions. After injection topical antibiotic drops were given to patients for one week and patients called for follow up after one week, one month, 2 month and 3 months. Same parameters BCVA, IOP, Dilated fundus examine and OCT was recorded on every visit. The final outcome i.e., change in central macular thickness was recorded. Results: In this study, out of 95 cases, 53.68%(n=51) were between 30-45 years of age while 46.32%(n=44) were between 46-60 years of age, mean ± SD was calculated as 46.83+7.82 years, 74.74%(n=71) were male and 25.26%(n=24) were females. Pre-treatment mean central macular thickness was recorded as 344.77+14.61µ which reduced to 154.57+16.57 µ, mean difference was recorded as 190.2+21.46 µ, p value was 0.0001 showing a significant difference. Conclusion: We concluded that intravitreal Bevacizumab significantly reduced central macular thickness in cases of chronic central serous chorioretinopathy.

Analysis of macular microvasculature and thickness after ICL implantation in patients with myopia using optical coherence tomography.

To investigate changes in macular vessels and thickness in myopic eyes after intraocular collamer lens (ICL) implantation using quantitative optical coherence tomography angiography (OCTA). This retrospective included 73 myopic eyes of 73 patients (average age, 27.53±6.16y) who underwent ICL implantation (28 eyes were Toric ICL). Axial length (AL), uncorrected visual acuity (UCVA), refractive dioptre (RD), intraocular pressure (IOP) and OCTA were measured and compared with before and 1wk, 1, and 3mo after surgery. OCTA was used to image vessel density (VD) and skeleton density (SD) in both the superficial (SCP) and deep capillary plexus (DCP). Central retinal thickness (CRT) and ganglion cell-inner plexiform layer thickness (GCT) were also measured. Changes between pre- and postoperative measurements were analysed by repeated measures analysis of variance. Compared with preoperative data, postoperative data on UCVA revealed significant improvements in all patients (P<0.05). However, there was no significant difference in IOP. After the operation, CRT and GCT exhibited significant changes (P<0.05). Among these measures, CRT was significantly higher at one and three months postoperative (all P<0.01). GCT was significantly higher at 1wk, 1, and 3mo postoperative (all P<0.01). Changes in VD and SD were nonsignificant in both the SCP and DCP. There was no difference in postoperative changes between the ICL and Toric ICL groups. ICL and Toric ICL implantation both have good efficacy and safety for myopic eyes, but macular area changes that occur after surgery need attention.

Effect of Hemodialysis on Peripapillary Choroidal Thickness Measured by Swept-Source Optical Coherence Tomography.

The aim was to investigate the effects of hemodialysis (HD) on peripapillary choroidal thickness (PCT) by swept-source optical coherence tomography and on other ophthalmologic parameters in patients with end-stage kidney disease. This was a prospective observational study. The authors evaluated 29 patients who underwent HD for end-stage kidney disease. Detailed ophthalmologic examinations and swept-source optical coherence tomography were performed immediately before and after HD. PCT was measured using the modification tool in the built-in OCT image viewer program. Changes in PCT before and after HD were statistically analyzed. The average PCT significantly decreased from 127.3±49.2 μm before HD to 117.1±50.9 μm after HD (P<0.001). A significant correlation was found between changes in PCT and macular choroidal thickness (ρ=0.547, P=0.002). Changes in mean ocular perfusion pressure did not significantly correlate with changes in PCT (ρ=-0.049, P=0.803). PCT significantly decreased after HD. HD could influence the optic nerve head and its surrounding structures.

Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.

To conduct a systematic review with network meta-analysis (NMA) of randomized clinical trials (RCTs) comparing panretinal photocoagulation (PRP) versus anti-vascular endothelial growth factor (VEGF) treatment alone or in combination with PRP, for proliferative diabetic retinopathy (PDR). PubMed, Medline and Embase databases were searched for RCTs comparing PRP versus intravitreal anti-VEGF therapy and/or combined PRP and intravitreal anti-VEGF for PDR. The primary outcome measures were the mean best corrected visual acuity (BCVA) change and the regression of neovascularization. Mean change of central macular thickness (CMT), the subgroup analyses of patients without diabetic macular oedema (DME) and the rate of vitreous haemorrhage and vitrectomy were secondary outcomes. Frequentist NMAs were performed. Twelve RCTs were included. For the 12-month mean BCVA change, NMA showed a better visual outcome in both the anti-VEGF group and combined group compared to PRP [anti-VEGF vs PRP, mean difference (MD)=3.42; standard error (SE)=1.5; combined vs PRP, MD=3.92; SE=1.65], with no difference between combined group and anti-VEGF (MD=-0.50; SE=1.87). No difference in neovascularization regression was found between PRP and anti-VEGF alone or in combination with PRP, but there was significant inconsistency (p=0.016). Subgroup analyses in patients without DME yielded no difference for the 12-month visual outcome between the three interventions, but with significant inconsistency (p=0.005). This NMA showed limited evidence of comparable efficacy in terms of neovascularization regression between PRP and anti-VEGF therapy alone or in combination with PRP, but better visual outcomes were associated with anti-VEGF use. Intravitreal anti-VEGF therapy could be a valid therapeutic option in association with PRP.

Study of changes in macular thickness following uneventful cataract surgery

Worldwide, cataract accounts 47.8%. Phacoemulsification cataract surgery had good results.Current study aimed to identify the macular thickness following uneventful phacoemulsification &amp; small incision cataract surgery method (SICS) comparison with visual acuity. In total (n=50) patients, 50% undergone SICS for one eye with bag polymethacrylate intraocular lens implantation and 50% undergone phacoemulsification method in one eye with in bag acrylic type of foldable IOL. Postoperatively patients followed on day 7, week 2 and week 4 and upto 3 months. The complete ophthalmological examination and OCT of macula was done at follow-up. Subclinical macular oedema noted in one case at 1, 2 and 4 week follow-up, but it was reduced at 3 month. There was statistical (p&amp;#60;0.05) significant difference observed in macular thickness between the preoperative &amp; post operative 1 week, post-operative 2 week &amp; post-operative 4 week followup in Phaco group. Eyes with SICS procedure also shown statistical (p&amp;#60;0.05) significant difference as above pre and postoperative follow-ups without affecting the final visual outcome. Post operatively, there was increased macular thickness without affecting the final visual outcome following phacoemulsification procedure. Subclinical macular edema noted at 1 week and reduced at 3 month.

Comparative study of retinal macular thickness changes in unilateral amblyopia with normal eye, using optical coherence tomography (OCT)

Comparative study of retinal macular thickness changes in unilateral amblyopia with normal eye, using optical coherence tomography (OCT)

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema

This study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment. The patients’ eyes received five consecutive intravitreal injections (2 mg aflibercept) every four weeks with two-week adjustments based on central subfield macular thickness (CSMT) changes. Injections were deferred when CSMT was stable. The number of injections, best-corrected visual acuity (BCVA), CSMT, and diabetic retinopathy severity scale scores were analysed. Compared to baseline, BCVA improved by + 9.1 letters at 52 weeks and was maintained with + 9.4-letter gain at 104 weeks (P < 0.001). Between baseline and 104 weeks, CSMT decreased from 489 to 298 μm (P < 0.001) and eyes with vision ≥ 20/40 increased from 17.4 to 43.5% (P = 0.007). The mean number of injections decreased from 8.5 in year one to 3.9 in year two. The injection interval was extended to ≥ 12 weeks in 56.5% of patients. The treat-and-extend regimen of aflibercept in DME showed 2-year efficacy comparable to that of fixed dosing regimens. The flexible dosing of this regimen reduced the number of injections in year two while maintaining efficacy.

Comparison of Macular Choroidal Thickness and Volume between Pseudoexfoliative Glaucoma and Pseudoexfoliative Syndrome.

Purpose To evaluate the difference in macular choroidal thickness and volume between patients with pseudoexfoliative glaucoma (PXG), patients with pseudoexfoliative syndrome (PEX), and normal controls. Methods This case-control study included 49 PXG patients (group A), 33 PEX patients (group B), and 42 sex-, age-, and axial length-matched healthy volunteer eyes (group C). The macular choroidal thickness and volume of all subjects studied were measured by enhanced depth imaging optical coherence tomography. Results The average macular (AM) choroidal thickness was 170.79 ± 50.18 μm, 184.65 ± 57.54 μm, and 206.46 ± 48.90 μm, and the average volume was 0.52 ± 0.15 μm3, 0.56 ± 0.17 μm3, and 0.63 ± 0.15 μm3 in groups A, B, and C, respectively. The macular choroidal thickness, the volumes of various macular regions, and the average choroidal thickness and volume in group A were lower than those in group C (all P < 0.05). There were no significant differences in the macular choroidal thickness, volumes of various macular regions, or average choroidal thickness or volume between group A and B (all P > 0.05). The macular choroidal thickness and volume of the TIM and SOM in group B were lower than those in group C (P < 0.05). There was no association between the macular choroidal thickness of various macular regions and visual field mean defect (MD) in group A (all P > 0.05). Conclusion The macular choroidal thickness in patients with PXG or PEX (TIM and SOM) is thinner than that in normal subjects. The macular choroidal thickness in patients with PXG is not significantly different from that in patients with PEX. The role of macular choroidal thickness changes in the glaucomatous damage of patients with PXG is still unclear.

Effect of Intravitreal Bevacizumab Injection before Panretinal Photocoagulation on the Prevention of Macular Edema Aggravation in Proliferative Diabetic Retinopathy.

Objective: To investigate the effects of intravitreal bevacizumab (IVB) injection before PRP on the prevention of macular edema (ME) in patients with PDR. Methods: This retrospective observational study included patients diagnosed with PDR treated by PRP with (combination group) or without (PRP alone group) preoperative IVB injection (1.25 mg/0.05 mL). The primary outcome measure was the change in the central macular thickness (CMT), while the secondary outcome measure was the change in visual acuity. Measurements were made before and at one, two, and three months after treatment. Results: In the PRP alone group, the mean baseline CMT of 277.8 μm increased to 290.4 μm at one month (p = 0.201) and 308.8 μm at two months (p = 0.002), followed by a decrease to 271.2 μm at three months (p = 0.437). In the combination group, the values at baseline and one, two, and three months after PRP were 322.9 μm, 295.4 μm (p = 0.002), 330.1 μm (p = 0.906), and 274.5 μm (p = 0.030), respectively. Visual acuity changes were comparable between the two groups at all time points. Conclusion: IVB injection before PRP leads to decreased CMT in comparison to CMT in patients with PRP alone.